Sinthia Bosnic-Anticevich is Professor at the Woolcock Institute of Medical Research, University of Sydney. Internationally recognised as a leader in in the field of respiratory medicines, she is the founder and Team Leader of the Quality Use of Respiratory Medicines Group, located at the Woolcock Institute, University of Sydney and Sydney Local Health District. The group focuses on generating new knowledge about the use of respiratory medicines from the patient, health care provider and societal perspective with output of over 120 research publications. The research of Sinthia and her group has changed the landscape of inhaler technique research; impacting on national and international treatment guidelines. Sinthia is on the executive of ARIA (Allergic Rhinitis in Asthma) and chair of Pharmacy ARIA, which is the leading global initiative for the management of Allergic Rhinitis in pharmacy. She is Vice President of the Respiratory Effectiveness Group (REG). Sinthia sits on several global advisory boards associated with the use of medicines in the management of respiratory diseases. Sinthia is actively involved in the practice of pharmacy and committed to the education of current and future health care providers around the use of respiratory medicines in practice.
Professor Doctor Moisés A. CALDERON MD PhD
Section of Allergy and Clinical Immunology, Imperial College London, Royal Brompton Hospital, London UK.
Professor Moisés A. Calderón is based at the Royal Brompton Hospital, Imperial College, National Heart and Lung Institute in London. In his current position as Director of the Clinical Trials Unit, Prof. Calderón is conducting clinical research investigating the efficacy and safety of allergen immunotherapy. In addition, he has participated as an independent allergy expert in various studies of allergen immunotherapy. Prof. Calderón acts with great clinical experience as a competent expert in safety committees and clinical investigations, focusing particularly on allergy sublingual immunotherapy tablets. He is an Executive Committee Member of the European Academy of Allergy and Clinical Immunology.
Prof. Calderón is the author of a long list of peer-reviewed publications in international journals on research topics in allergy – and continuously acts as a reviewer on scientific publications. He has participated as a key opinion leader on allergen immunotherapy at many international meetings.
Prof. Calderón was educated at the University of Costa Rica were he obtained an MD in Internal Medicine and at the University of London were he obtained his PhD in Allergy and Clinical Immunology. He joined Imperial College London and the Royal Brompton Hospital in 2002. Prof. Calderón has worked as an academic with the Cochrane Group at Oxford University.
Prof. Calderón has been part of the Executive Working Group of the Global Alliance Against Chronic Respiratory Diseases (GARD) of the World Health Organization.
In addition to his clinical work and comprehensive clinical research activity Prof. Calderón is also involved with lecturing at major international courses and meetings covering the areas of asthma, basic clinical allergy, and allergen immunotherapy.
Giorgio Walter Canonica
Allergist and Pulmonologist Giorgio Walter is Professor of Respiratory Medicine at Humanitas University
& Director Personalized Medicine Asthma & Allergy Center at Humanitas Research Hospital-Milano Italy
Professor Canonica first specialised in pulmonary diseases after receiving his medical degree from the
University of Genoa, Italy. He then specialised in allergy and clinical immunology at Florence University,
Italy. He subsequently conducted clinical immunology and allergology research at several European
Universities and Institutes, in addition to two years at the Medical University of South Carolina, USA.
Since returning to the University of Genoa in 1995, Professor Canonica has held a number of academic
positions, including Director of the Speciality School of Allergy and Clinical Immunology, Director of the
Specialty School of Pulmonary Diseases and Chairman of the Department of Medical Specialties (University
Hospital San Martino Genoa, Italy). He is a Board Member of ARIA-Allergic Rhinitis and its Impact on Asthma
and helped to develop their guidelines.
He has been President of WAO-World Allergy Organization, Interasma-Global Asthma Association, currently VicePresident of REG-Respiratory Effectiveness Group.
He is Steering Committee Member of SANI-Severe Asthma Network Italy.
Family Physician practicing in York Region, Ontario, Canada.
Medical Director LHIN Pulmonary Rehabilitation Clinics
Chairperson of the Family Physician Airways Group of Canada (www.fpagc.com)
Past- Chairperson of the Respiratory Section of the College of Family Physicians of Canada
Senate member of the International Primary Care Respiratory Group
President of the IPCRG 5th biennual world scientific meeting, “Making Every Breath Count” Toronto June 2-5, 2010
Chair of the Council of Organizing Members of the Canadian Network for Respiratory Care.
Member of Past Canadian Consensus Guidelines for H pylori, Asthma, COPD and Sinusitis
Representative of the College of Family Physicians of Canada to the SARS clinical working group.
Member of Chronic Respiratory Disease Surveillance Advisory Committee (Public Health Agency of Canada)
Member of the Health Canada Section on Allergy and Respiratory Therapies
Co-Chair, Health Quality Ontario COPD Community Management standards committee
Board member, Thrombosis Canada
Vice President, Respiratory Effectiveness Group
Marc Miravitlles is a Pulmonologist at the Hospital Universitari Vall d’Hebron in Barcelona, Spain. He obtained his MD at the Universitat de Barcelona, Barcelona, Spain and then specialised in Respiratory Medicine at Hospital Vall d'Hebron. His primary research interests include chronic obstructive pulmonary disease (COPD), alpha-1-antitrypsin deficiency (AAT), lung defence mechanisms and respiratory infections. He serves on various medical committees and is a member of numerous professional societies, including the Spanish Society of Pneumology and Thoracic Surgery (SEPAR), where he served as Secretary from 1999 until 2003 and responsible for International Relationships from 2006 until 2012. Dr Miravitlles was Chair of the Respiratory Infections Group of the European Respiratory Society (ERS) from 2008 to 2011 and was the Guidelines Director of the ERS from 2015 to 2018. He has acted as a consultant for the development of different international guidelines of COPD, including the American Thoracic Society (ATS)/ERS task force on outcomes in COPD, the ERS/ATS guidelines on exacerbations of COPD and the ERS statement on management of alpha-1 antitrypsin deficiency. He is also a consultant of the Spanish Ministry of Health for the development of the National Strategy Against COPD (2009 to present). He is the coordinator of the Spanish National Guidelines for COPD (GesEPOC from 2012).
Prof. Papadopoulos is Professor
of Allergy and Paediatric Allergy at the University of Manchester, UK, and the Chair of Allergy and
Pediatric Allergy at the University of Athens (NKUA), Greece.
He has extensive clinical and educational experience in paediatric allergy, having headed for many years a unit caring for more than 7,000 children with allergic diseases yearly, implementing state-of-the-art interventions and training medical students, resident paediatricians and allergists.
His research focus is the interface between infection and allergic disease, with an emphasis on asthma exacerbations and food allergy. He is the Coordinator of the EU-funded CURE project. He has extensive collaborations in the context of EU projects, such as PreDicta, GA2LEN, EUROPREVALL, iFAAM and FAST.
Prof. Papadopoulos has published over 300 papers (h-index: 70), has received several international awards and is invited to speak at international scientific meetings some 30 times a year. Moreover, he has served or is serving on the boards of EAACI, GA2LEN, WAO, EFA and ARIA. He was the 2013–2015 President of EAACI and is currently the President of the Respiratory Effectiveness Group (REG).
Alberto Papi is Professor of Respiratory Medicine at the University of Ferrara, Italy, and Director of the
Respiratory Unit of the Department of Emergency Medicine, S. Anna University Hospital, Ferrara, Italy.
He trained in Respiratory Medicine at the University of Parma, before spending 4 years in the UK as a Clinical Research Fellow at the University of Southampton, where he is an Honorary Clinical Lecturer.
He has coordinated several pivotal studies in asthma and COPD, and has authored more than 300 articles in peer-reviewed journals.
Nicolas Roche is Professor of Respiratory Medicine at Cochin Hospital, University of Paris Descartes,
France. His major areas of interest are COPD and asthma with particular focus on inhaled therapy, disease
phenotypes, assessment tools, treatment strategies and real-life research.
Professor Roche is guidelines director of the ERS, member of the GOLD science committee, and President of Société de Pneumologie de Langue Française. He co-chaired the 2018 ERS Congress and is a member of the ERS Clinical Research Collaboration (CRC) working group and ERS Science Council. He is vice-president of the Respiratory Effectiveness Group and member of the American Thoracic Society and of the Asthma Drug Management Improvement Team. He coordinates French guidelines on COPD and is a consultant for French institutions for the development of national programs on COPD.
Professor Roche has authored more than 250 research articles in international peer-reviewed journals and edited or co-edited several books on COPD. He is Associate Editor of the European Respiratory Review and the Clinical Respiratory Journal.
Specialized in Family and Community Medicine and working as a Family Physician for the Balearic Health
Service in Palma de Mallorca (Spain) where he is responsible in teaching activities and research. He is the
chair of the Primary Care Chronic Respiratory Diseases Research Unit at the Balearic Health Research
Institute (IdisBa) in Palma (Spain).
From 2010-2012 he was the President of the International Primary Care Respiratory Group (IPCRG) www.theipcrg.org and member of the Board of directors from 2008 to 2014. He is member of the international editorial board of the Primary Care Respiratory Medicine, a Nature publishing group journal.
His educator profile and research activities aim to encourage family doctors in the diagnostic process and follow up of COPD, asthma and other chronic respiratory diseases. Specifically, he follows a research line on early diagnostic spirometry and leads the spirometry implementation plan for the Balearic Health Service. He is also leading MAJORICA, a real-life chronic respiratory cohort project including a population of more than 70.000 patients from the Balearic Islands in Spain. He has developed and collaborate in many different educational projects for COPD and asthma for IPCRG and Spanish family physicians’ organization -semFYC- . He is also involved in guidelines development and actively collaborating in COPD Strategic National plans in Spain. In the year 2012 he was winner of the Wonca Europe Award of Excellence in Health Care: The 5-Star Doctor 2012.
Dermot was a GP for over 30 years in the UK. He has championed respiratory and allergy care in the primary care environment over that time. He established the chair of Primary Care Respiratory Medicine at the University of Aberdeen to research "primary care solutions for primary care problems", He is active in research and is a collaborator at theAsthma UK Centre for Applied Research and is also very active in EAACI.
Prof Joan B Soriano
Associate Professor of Medicine, Universidad Autónoma de Madrid, Cátedra UAM-Linde, and Senior
Investigator at the Instituto de Investigación Hospital Universitario de la Princesa-IISP, Madrid, Spain
Joan B Soriano graduated in medicine in 1993 and received his PhD in epidemiology and methodology of biomedical research in 1996, both from the Universitat Autònoma de Barcelona. He completed his education in epidemiology with a Master of Science at the Erasmus University, Rotterdam, The Netherlands, and a post-doctoral stay at the Johns Hopkins School of Public Health, in Baltimore, USA. He worked in the pharmaceutical industry in the UK from 1998, and later in the USA from 2003. Then, in 2005 he moved back to CIMERA in Mallorca, Spain. He serves in the GesEPOC COPD guidelines, directed the SEPAR’s Foreign Affairs, participates in several committees of the Ministry of Health of Spain, and collaborates extensively with both the ERS and CHEST. He spends most of his time dedicated to research on COPD and other respiratory conditions, aging and tobacco, the design of new clinical trials and translational medicine. Since 2007 he is an Associate Editor of the European Respiratory Journal and since 2012 of the Lancet Respiratory Medicine. He has published over 270 papers and over 20 book chapters. In May 2011, he received the Josep Trueta Award for scientific and medical achievements, and in 2014 was appointed FCCP of Chest and Foundational Fellow of the ERS.
Professor David Price, FRCGP
Primary Care Respiratory Society Professor of Primary Care Respiratory Medicine at the University of
Managing Director of Observational and Pragmatic Research Institute, Singapore
Managing Director of Optimum Patient Care, Australia and UK
Professor David Price is head of The Observational & Pragmatic Research Institute (Singapore) and Optimum Patient Care (Australia and UK), and is Primary Care Respiratory Society Professor of Primary Care Respiratory Medicine at the University of Aberdeen (UK). His area of interest lies in real life respiratory and allergy research. To date he has authored over 490 peer-reviewed publications and is responsible for approximately US$50 million in research and clinical development grants. In addition he established the Optimum Patient Care Research Database (OPCRD; http://opcrd.co.uk/) with over 6.3 million patients, and the first International Severe Asthma Registry (ISAR; http://isaregistries.org/) with over 20 countries collaborating. He is currently Editor-in-Chief of Pragmatic and Observational Research and member of the editorial board of several respiratory journals, including The Lancet Respiratory Medicine.
Professor Liam Heaney is Professor of Respiratory Medicine at Queens University Belfast, N Ireland, who trained in Northern Ireland and the Royal Brompton Hospital in London. He is Director of the Northern Ireland Regional Difficult Asthma Service which over the past 10 years has developed a programme of optimal clinical assessment in this population including multi-disciplinary systematic assessment and identification and management of poor adherence. He has chaired the British Thoracic Society Specialist Advisory Group for Asthma, the Evidence Review Group for Difficult Asthma for the British Thoracic Society / Scottish Intercollegiate Guideline on Asthma Management and has been a member of the National Steering Committee for the UK Asthma Guidelines. He is a member of the Medical Research Council Population and Systems Medicine Board and Experimental Medicine Panel. He co ordinates the UK Severe Asthma Registry and NICE UK Thermoplasty Registry. He is Academic Lead the Medical Research Council UK Refractory Stratification Programme (http://www.rasp.org.uk) and has published extensively on the clinical assessment and management of difficult to control asthma in adults
Nicola A. Hanania, MD, MS, FCCP, FACP, FRCP(C), FERS
Associate Professor of Medicine
Section of Pulmonary and Critical Care Medicine
Airways Clinical Research Center
Baylor College of Medicine
Nicola A. Hanania, MD, MS, is associate professor of medicine in the Section of Pulmonary and Critical Care Medicine and director of the Airways Clinical Research Center at the Baylor College of Medicine in Houston, Texas. He completed his medical training at the University of Jordan in Amman, Jordan, followed by a residency in internal medicine and a fellowship in pulmonary medicine at the University of Toronto, Toronto, Canada. He subsequently completed a fellowship in critical care medicine at Baylor College of Medicine, where he later earned a master’s degree in clinical investigation.
As a fellow of the American College of Chest Physicians (ACCP), Dr Hanania has served on the Board of Regents and as chair of the Clinical Pulmonary Medicine, Airways Disorders Networks and Council of NetWorks for this organization. He has been on the Board of Trustees of the Chest Foundation since 2012. In addition, he served as a member of the Health Policy Committee of the American Thoracic Society (ATS). He is a fellow of the European Respiratory Society (ERS), and the Royal College of Physicians and Surgeons of Canada. He has served on several guideline and workshop panels, including the ACP (American College of Physicians)/ATS/ACCP/ERS clinical practice guidelines on chronic obstructive pulmonary disease (COPD) and the CTS (Canadian Thoracic Society)/ACCP COPD exacerbations guidelines.
Dr Hanania has received multiple awards, including the ACCP’s Distinguished Scholar in Respiratory Health, ACCP distinguished CHEST educator (DCE), ACCP Humanitarian Award, Career Investigator Award (K23) from the National Institutes of Health, Fulbright and Jaworski’s Faculty Excellence Award for Teaching and Evaluation, and the Award for Excellence in Teaching from the Department of Medicine at Baylor College of Medicine. Baylor also named him to the Academy of Distinguished Educators for 2003 to 2010. He is a deputy editor of Respiratory Medicine and is associate editor of the journals Therapeutic Advances in Respiratory Disease, Current Opinion in Pulmonary Medicine (Asthma Section), and Pulmonary Pharmacology and Therapeutics.
Dr Hanania’s research interests focus on the pharmacology and management of asthma and COPD. He has published more than 200 peer-reviewed papers, book chapters, editorials, and reviews on these topics. He is actively involved in clinical trials investigating novel treatments. He is principal investigator for the American Lung Association Airways Clinical Research Center at Baylor College of Medicine, as well as principal investigator or co-investigator in several clinical trials in asthma and COPD. Dr Hanania has been invited and has lectured widely at local, regional, national, and international meetings.
Dr Omar Usmani, MBBS, PhD, FHEA, FRCP, FERS
Omar Usmani is a Reader and Consultant Physician in Respiratory Medicine at the National Heart and Lung
Institute (NHLI), Imperial College London and Royal Brompton Hospital.
He qualified in Medicine at King’s College London and completed his PhD at Imperial College London for which he received the 2005 NHLI Imperial College PhD Prize for the best thesis.
His clinical research themes are Inhaled Drug Delivery, Airways Physiology, Lung Imaging, Respiratory Pharmacology and Tele-monitoring / E-health. He is co-investigator and Lead Clinical PI, on an EU HORIZON 2020 grant, myaircoach, to investigate the role of Tele-monitoring and E-health in asthma self-management.
He is REG Vice President of Scientific Outputs, Secretary of Assembly 5 (Airway Diseases, Asthma and COPD) at the ERS, Chair of UKIG (UK Inhaler Group), Vice-Chair of Drug Delivery to the Lungs, and Europe Liaison of International Society of Aerosols in Research (ISAM).
In 2015, he received one of the highest accolades in aerosol science, the Thomas T Mercer Award from the American Association of Aerosol Research (AAAR) and ISAM, recognizing his international research excellence in pharmaceutical aerosols and inhalable materials.
In 2019, he was awarded the Fellowship of The European Respiratory Society (FERS).
Professor of Paediatric Respiratory Medicine, Imperial College London
Honorary Consultant, Royal Brompton Hospital, London
My research and clinical experience focusses on the investigation of mechanisms underlying the inception of severe asthma and preschool wheeze in children, finding novel therapies to improve control, reduce exacerbations and to achieve disease modification. I have developed a programme of research that is translational, involving an integrated approach to answering questions using both bronchoscopic airway samples from carefully clinically phenotyped children, coupled with an age appropriate neonatal mouse model. I am currently leading a national clinical trial, funded by NIHR, comparing the efficacy of two biologics, omalizumab and mepolizumab in children with severe asthma.
My research programme enables the investigation of mechanisms underlying the onset of severe preschool wheeze, factors that determine progression to childhood asthma with the ultimate aim of identifying disease modifying therapies for preschool wheeze and childhood severe asthma.
Lorcan McGarvey is Professor of Respiratory Medicine at Queen’s University of Belfast (QUB) and Consultant Respiratory Physician at the Royal Victoria Hospital, Belfast, Northern Ireland. He graduated with Honours in Medicine from QUB in 1990 and trained in respiratory medicine in Belfast and Sydney, Australia. He is Lead Clinician for the Northern Ireland Respiratory Clinical Research Network. His main programme of research has focused on clinical and scientific aspects of airways disease and in particular chronic cough, asthma and COPD. He is an Expert member on the European Respiratory Society Cough Task Force and currently serves on the American College of Chest Physicians Cough Guidelines Expert Committee. He leads the recently awarded European Respiratory Society NEuroCOUGH Clinical Research Consortium. Professor McGarvey has published extensively on airways disease and received grant income from EU (INTERREG Va), MRC, Asthma UK, NC3R, British Heart Foundation, Northern Ireland Chest Heart & Stroke, and Higher Education Authority North-South Programme. He is a Fellow of the Royal College of Physicians and in 2011 was elected to the Association of Physicians of Great Britain and Ireland.
Professor Harrison is Professor of Asthma and Honorary Consultant at the University of Nottingham and Head
of Respiratory Services at Nottingham University Hospitals NHS Trust, where he works as a severe asthma
Professor Harrison has published pivotal studies looking at the best ways to predict and prevent asthma exacerbations, focusing on real-life, pragmatic studies, which have shaped national and international guidelines. His interests also include improving the diagnosis and management of less severe asthma in primary care and the evaluation of biological treatment in specialist care. Current interests include redefining our definition of severe exacerbations and phenotyping severe exacerbations with the aim of reducing systemic corticosteroid use.
Leif Bjermer, MD PhD
Leif Bjermer, MD PhD
Professor of Allergy and Asthma research
University of Lund, Sweden
Borne November 27th 1952 in Hörby, Southern Sweden
Married, three children Christoffer 36 , Jessica 34 & Johannes 11
Medical school, Umeå University 1977-1986
Specialist in Lung Medicine 1987
Specialist in Allergology 2000
Thesis: Bjermer L. Sarcoidosis and extrinsic allergic alveolitis.Bronchoalveolar lavage studies on two granulomatous disorders of the lung. Universitet of Umeå, 1987;196
Position: 1992-2002 Professor and head of the department of lung medicine, University of Trondheim, Norway. From June 2002 - Professor at the dept of Respiratory Medicine and Allergology, University hospital of Lund, Sweden.
Supervision (Completed) : Main supervisor for 18 students. Co-supervisor for 12
Appointments: Chief Editor of Breath 2009-2012, Chief Editor of Respiratory Medicine 2002-9. Chief Editor of ECRJ since 2014. Member of ATS, ACCP, ERS, EAACI. Chairman of EAACI asthma section 2014-15
The first years in Umeå was dedicated studies on interstitial lung disorders and development of fibrosis, bronchoalveolar lavage (BAL) studies. The importance of constitutive cells, especially mast cells has since then been a theme in inflammatory research also including other inflammatory airway disorders. The studies have mostly been translational including basic science, animal experimental research combined with invasive and non-invasive clinical experimental research.
From 1992 to 2002, the research focus shifted from ILD to obstructive lung disorders with asthma development, especially in elite cross-country skiers, as a major interest, epidemiology, provocation tests and bronchoscopy. During the same period I was also involved in a large epidemiological survey on obstructive lung disorders in North Tröndelag, studying nearly 10 000 adults and 10 000 adolescents sampled from a population cohort of 92 000.
Since 2002 I have moved to Lund in southern Sweden and is currently appointed as professor in asthma and Allergology. A translational research group with special focus on peripheral airway inflammation, reparation and regenation has been established. The primary study populations are asthma and COPD, but we have also ongoing parallel projects on interstitial fibrosing lung disorders and on lung transplant patients with or without chronic rejection. Tissue derives from bronchial and transbronchial bronchoscopy sampling and from surgical resections. Non-invasive parameters derived from advanced physiology, imaging techniques and biomarkers are studied in parallel with morphology and cell and matrix biological research.
During the last years I have devoted an increasing interest in practical aspects of managing asthma and COPD, from randomized clinical trials to a more “real life” setting. I also run a clinical trial unit performing mainly phase II studies.
Scientific publications: June 2019: 273 original articles, 106 reviews, reports and book chapters
Maria Molina-Molina, MD, PhD
Maria Molina-Molina, MD, PhD
Maria Molina has been working in IPF for twenty years, including clinical and research areas. She leads the ILD Unit at Bellvitge University Hospital, the academic ILD program at the University of Barcelona, and the research group of Pulmonology of IDIBELL. Thesis director of seven new ILD professionals and author of one hundred indexed research articles. Coordinator of clinical guidelines and trials in ILDs. She contributes in the increase of ILD trained professionals. Participant of the IPF patient charter and Steering Committee of the EU-IPF Federation, she has contributed in improving IPF awareness and policymakers.
Professor George Christoff, MD, PhD, MPH
Professor at the Faculty of Public Health, Medical University – Sofia. Lead, Allergy out-patient clinic, Acibadem CityClinic Tokuda Medical Centre, Sofia, Bulgaria. He has more than 130 publications in the field of allergy, clinical epidemiology, quality of life, health economics and HTA. Prof. Christoff is a specialist in internal diseases, clinical allergology and health economics. He has 31 years of clinical experience as a practising allergist. His academic career started as a faculty member to the Medical Faculty, Medical University – Sofia. Since 2009 he is a lecturer in health economics at the Faculty of Public Health, Medical University – Sofia. In 2014 he was appointed lead to the department of Health technology assessment, Faculty of Public Health in the establishment of which he had an active role. Prof. Christoff is a course leader in HTA, evidence-based medicine, health economics and health management for bachelor, master and doctoral degree students at the Faculty of Public Health. He is a member of EUPHA, NAHPM, BSA, EAACI, REG.